1
|
Ji H, Wu G, Li Y, Wang K, Xue X, You S, Wu S, Ren T, He B, Shi X. Self-Albumin Camouflage of Carrier Protein Prevents Nontarget Antibody Production for Enhanced LDL-C Immunotherapy. Adv Healthc Mater 2020; 9:e1901203. [PMID: 31814301 DOI: 10.1002/adhm.201901203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 11/07/2019] [Indexed: 11/05/2022]
Abstract
Elevated low-density lipoprotein cholesterol (LDL-C) increases the risk of atherosclerotic cardiovascular disease. Peptide-based PCSK9 vaccines have shown a promising prospect of reducing LDL-C. In peptide vaccine (pVax) design, the peptide antigens need to conjugate with carrier protein (CP). However, CP incorporation can induce undesirable anti-CP antibodies, which sterically mask peptide epitopes from being recognized by specific B cells and impair subsequent therapeutically antibody production. This epitopic suppression has posed a barrier in clinical translation of conjugate vaccines all along. A model CP (keyhole limpet hemocyanin, KLH) is herein camouflaged with serum albumin (SA) into hybrid nanocarriers (SA@N), with PCSK9 peptide being anchored onto the surface to form nanovaccine (SA@NVax). Such camouflage of KLH via high "self" SA coverage is able to inhibit KLH from extracellular immune recognition and prevent detectable anti-KLH antibody production. Furthermore, the nanovaccine around 70 nm stabilized by intermolecular disulfide network is ideal for internalization and biodegradation by antigen presenting cells as well as better retention in draining lymph nodes and spleen. As expected, the SA@NVax efficiently primes higher anti-PCSK9 IgG antibody titer than PCSK9 pVax.
Collapse
Affiliation(s)
- Haiying Ji
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| | - Guangxi Wu
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| | - Yongyong Li
- Institute for Biomedical Engineering and Nano ScienceShanghai East HospitalTongji University School of Medicine Shanghai 200092 China
| | - Kun Wang
- Institute for Biomedical Engineering and Nano ScienceShanghai East HospitalTongji University School of Medicine Shanghai 200092 China
| | - Xiaomei Xue
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| | - Shasha You
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| | - Shengming Wu
- Institute for Biomedical Engineering and Nano ScienceShanghai East HospitalTongji University School of Medicine Shanghai 200092 China
| | - Tianbin Ren
- School of Materials Science and EngineeringTongji University Shanghai 200092 China
| | - Bin He
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| | - Xueyin Shi
- Department of Anesthesiology and SICUXinhua HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200092 China
| |
Collapse
|
2
|
Behrendt I, Prądzińska M, Spodzieja M, Czaplewska P, Kołodziejczyk AS, Szymańska A, Kasprzykowski F, Lundström SL, Zubarev RA, Rodziewicz-Motowidło S. Identification and characterization of antibodies elicited by human cystatin C fragment. J Mol Recognit 2017; 31. [PMID: 29205549 DOI: 10.1002/jmr.2689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 10/23/2017] [Accepted: 10/28/2017] [Indexed: 11/11/2022]
Abstract
Amyloid formation is associated with a number of neurodegenerative diseases that affect the independence and quality of life of aging populations. One of rather atypical, occurring at a young age amyloidosis is hereditary cystatin C amyloid angiopathy (HCCAA) related to aggregation of L68Q variant of human cystatin C (hCC). Human cystatin C plays a very important role in many aspects of human health; however, its amyloidogenic properties manifested in HCCAA present a real, lethal threat to some populations and any work on factors that can affect possible influencing hCC aggregation is not to overestimate. It was proved that interaction of hCC with monoclonal antibodies suppresses significantly hCC dimerization process. Therefore, immunotherapy seems to be the right approach toward possible HCCAA treatment. In this work, the hCC fragment encompassing residue 60-70 (in 2 variants: linear peptide and multiple antigenic peptide) was used as an immunogen in rabbit immunization. As a result, specific anti-hCC antibodies were found in both rabbit sera. Surprisingly, rabbit antibodies were obtained after immunization with only a short peptide. The obtained antibodies were characterized, and their influence on the aggregation propensity of the hCC molecules was evaluated. The antibodies turned out not to have any significant influence on the cystatin C dimerization process. Nevertheless, we hope that antibodies elicited in rabbits by other hCC fragments could lead to elaboration of effective treatment against HCCAA.
Collapse
Affiliation(s)
| | | | | | - Paulina Czaplewska
- Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland
| | | | | | | | - Susanna L Lundström
- Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden
| | - Roman A Zubarev
- Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden
| | | |
Collapse
|
3
|
Marciani DJ. A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies. J Neurochem 2016; 137:687-700. [PMID: 26990863 DOI: 10.1111/jnc.13608] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Revised: 02/25/2016] [Accepted: 02/26/2016] [Indexed: 12/16/2022]
Abstract
The promising results obtained with aducanumab and solanezumab against Alzheimer's disease (AD) strengthen the vaccine approach to prevent AD, despite of the many clinical setbacks. It has been problematic to use conjugated peptides with Th1/Th2 adjuvants to induce immune responses against conformational epitopes formed by Aβ oligomers, which is critical to induce protective antibodies. Hence, vaccination should mimic natural immunity by using whole or if possible conjugated antigens, but biasing the response to Th2 with anti-inflammatory adjuvants. Also, selection of the carrier and cross-linking agents is important to prevent suppression of the immune response against the antigen. That certain compounds having phosphorylcholine or fucose induce a sole Th2 immunity would allow antigens with T-cell epitopes without inflammatory autoimmune reactions to be used. Another immunization method is DNA vaccines combined with antigenic ones, which favors the clonal selection and expansion of high affinity antibodies needed for immune protection, but this also requires Th2 immunity. Since AD transgenic mouse models have limited value for immunogen selection as shown by the clinical studies, screening may require the use of validated antibodies and biophysical methods to identify the antigens that would be most likely recognized by the human immune system and thus capable to stimulate a protective antibody response. To induce an anti-Alzheimer's disease protective immunity and prevent possible damage triggered by antigens having B-cell epitopes-only, whole antigens might be used; while inducing Th2 immunity with sole anti-inflammatory fucose-based adjuvants. This approach would avert a damaging systemic inflammatory immunity and the suppression of immunoresponse against the antigen because of carrier and cross-linkers; immune requirements that extend to DNA vaccines.
Collapse
|
4
|
|